European Neuropsychopharmacology
Volume 20, Issue 4 , Pages 218-225 , April 2010

(+)-UH 232, a partial agonist of the D3 dopamine receptors, attenuates cognitive effects of angiotensin IV and des-Phe6-angiotensin IV in rats

Received 7 May 2009 ,Revised 24 November 2009 ,Accepted 26 November 2009.

References 

  1. Ader R, Weijnen JAWM, Moleman P. Retention of a passive avoidance responses as a function of the intensity and duration of electric shock. Psychon. Sci. 1972;26:125–129
  2. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, et al. Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase. J. Biol. Chem. 2001;276:48623–48626
  3. Barik S, de Beaurepaire R. Dopamine D3 modulation of locomotor activity and sleep in the nucleus accumbens and in lobules 9 and 10 of the cerebellum in the rat. Prog. Neuro-Psychopharm. Biol. Psychiatr. 2005;29:718–726
  4. Braszko JJ. Involvement of D1 dopamine receptors in the cognitive effects of angiotensin IV and des-Phe6 angiotensin IV. Peptides. 2004;25:1195–1203
  5. Braszko JJ. D2 dopamine receptor blockade prevents cognitive effects of Ang IV and des-Phe6-Ang IV. Physiol. Behav. 2006;88:152–159
  6. Braszko JJ. Dopamine D4 receptor antagonist L745, 870 abolishes cognitive effects of intracerebroventricular angiotensin IV and des-Phe6-Ang IV in rats. Eur. Neuropsychopharmacol. 2009;19:85–91
  7. Braszko JJ, Walesiuk A, Wielgat P. Cognitive effects attributed to angiotensin II may result from its conversion to angiotensin IV. J. Renin. Angiotensin Aldosterone Syst. 2006;7:168–174
  8. Braszko JJ, Wielgat P, Walesiuk A. Effect of D3 dopamine receptors blockade on the cognitive effects of angiotensin IV in rats. Neuropeptides. 2008;42:301–309
  9. Braszko JJ, Wiśniewski K, Kupryszewski G, Witczuk B. Psychotropic effects of angiotensin II and III in rats: locomotor and exploratory vs. cognitive behaviour. Behav. Brain Res. 1987;25:195–203
  10. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Ann. Rev. Pharmacol. Toxicol. 2001;41:237–260
  11. Chen G, Kittler JT, Moss SJ, Yan Z. Dopamine D3 receptors regulate GABAA receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens. J. Neurosci. 2006;26:2513–2521
  12. Demaegdt H, Vanderheyden P, de Backer JP, Mosselmans S, Laeremans H, Le MT, et al. Endogenous cystinyl aminopeptidase in Chinese hamster ovary cells: characterization by [125I]Ang IV binding and catalytic activity. Biochem. Pharmacol. 2004;68:885–892
  13. Droste DW, Ritter MA, Dittrich R, Heidenreich S, Wichter T, Freund M, et al. Arterial hypertension and ischaemic stroke. Acta Neurol. Scand. 2003;107:241–251
  14. Du F, Li R, Huang Y, Li X, Le W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur. J. Neurosci. 2005;22:2422–2430
  15. Ennaceur A, Meliani K. A new one-trial test for neurobiological studies of memory in rats. III. Spatial vs nonspatial working memory. Behav. Brain. Res. 1992;51:83–92
  16. Gard PR. Cognitive-enhancing effects of angiotensin IV. BMC Neurosci. 2008;9(Suppl 2):S15
  17. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 2000;52:415–472
  18. Gavras, H., Brunner, HR. (2001) Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure. Hypertension 37, 342–345.
  19. Griffon N, Pilon C, Schwartz J-Ch, Sokoloff P. The preferential dopamine D3 receptor ligand, (+)-UH 232, is a partial agonist. Eur. J. Pharmacol. 1995;282:R3–R4
  20. Harding JW, Cook VI, Miller-Wing AV, Hanesworth JM, Sardinia MF, Hall KL, et al. Identification of an AII(3–8) [AIV] binding site in guinea pig hippocampus. Brain Res. 1992;583:340–343
  21. Jeanblanc J, He D-Y, McGough NNH, Logrip ML, Phamluong K. The dopamine D3 receptor is part of a homeostatic pathway regulating ethanol consumption. J. Neurosci. 2006;26:1457–1464
  22. Kennedy LA, Zigmond MJ. The behavioural effects of D-amphetamine are correlated with its effects on cAMP in different brain regions. Brain Res. 1979;168:408–413
  23. Kothari SA, Le MK, Gandhi PJ. Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications. J. Thromb. Thrombolysis. 2003;15:217–225
  24. Lahti AC, Weiler M, Carlsson A, Tamminga CA. Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. J. Neural. Transm. 1998;105:719–734
  25. Le MT, Vanderheyden PML, Szaszak M, Hunyady L, Vauquelin G. Angiotenisin IV is a potent agonist for constitutive active human AT1 receptors: distinct roles of the N- and C-terminal residues of angiotensin II during AT1 receptor activation. J. Biol. Chem. 2002;277:23107–23110
  26. Lin H, Saish SGN, Strange PG. Assays for enhanced activity of low efficacy partial agonists at the D2 dopamine receptor. Brit. J. Pharmacol. 2006;149:291–299
  27. Noda K, Saad Y, Karnik SS. Interaction of Phe8 of angiotensin II with Lys199 anf His256 of AT1 receptor in agonist activation. J. Biol. Chem. 1995;270:28511–28514
  28. Pellow S, Chopin P, Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Meth. 1985;14:149–167
  29. Randrup A, Munkvad I. Pharmacology and physiology of stereotyped behaviour. J. Psychiatr. Res. 1974;11:1–10
  30. Sardinia MF, Hanesworth JM, Krebs LT, Harding JW. AT4 receptor binding characteristics: D-amino acid- and glycine-substituted peptides. Peptides. 1993;14:949–954
  31. Sleight P. The role of angiotensin-converting enzyme inhibitors in the treatment of hypertension. Curr. Cardiol. Rep. 2001;3:511–518
  32. Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-Ch. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990;347:146–151
  33. Stragier B, Sarre S, Vanderheyden P, Vauquelin G, Fournie-Zaluski MC, Ebinger G, et al. Metabolism of angiotensin II is required for its in vivo effect of dopamine release in the striatum of the rat. J. Neurochem. 2004;90:1251–1257
  34. Stragier B, Demaegdt H, de Bundel D, Smolders I, Sarre S, Vauquelin G, et al. Involvement of insulin-regulated aminopeptidase and/or aminopeptidase N in the angiotensin IV-induced effect on dopamine release in the striatum of the rat. Brain Res. 2007;1131:97–105
  35. Stragier B, Hristova I, Sarre S, Ebinger G, Michotte Y. In vivo characterization of the angiotensin-(1-7)-induced dopamine and γ-aminobutyric acid release in the striatum of the rat. Eur. J. Neurosci. 2005;22:658–664
  36. Strange PG. Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends Pharmacol. Sci. 2008;29:314–321
  37. Svensson K, Johansson AM, Magnusson T, Carlsson A. (+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists. Naunyn-Schmiedeberg's Arch. Pharmacol. 1986;334:234–245
  38. Wright JW, Yamamoto BJ, Harding JW. Angiotensin receptor subtype mediated physiologies and behaviours: new discoveries and clinical targets. Prog. Neurobiol. 2008;84:157–181
  39. Van Kampen JM, Robertson HA. A possible role for dopamine D3 receptor stimulation in the induction of neurogenesis in the adult rat substantia nigra. Neuroscience. 2005;136:381–386
  40. Vogel M, Pfeifer S, Schaub RT, Grabe H-J, Barnow S, Freyberger HJ, et al. Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology. 2004;50:305–310
  41. Xi Z-X, Gilbert J, Campos AC, Kline N, Ashby ChR, Hagan JJ, et al. Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology. 2004;176:57–65

PII: S0924-977X(09)00277-6

doi: 10.1016/j.euroneuro.2009.11.012

European Neuropsychopharmacology
Volume 20, Issue 4 , Pages 218-225 , April 2010

Article Tools

* Image Usage & Resolution